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Letters to the Editor
Masked Hypertension and
White-Coat Hypertension Prognosis
The recent published study by Ohkubo et al. (1) investigated the
interesting relationship between masked hypertension and the risk
of cardiovascular mortality and morbidity in the future. This
10-year follow-up study demonstrated that the relative hazards of
masked hypertensive patients and sustained hypertensive patients
were significantly higher than the hazards for white-coat hyper-
tensive patients and patients with normal blood pressure (BP).
However, there are some limitations that deserve special atten-
tion. The BP level may have been decreased coincidently during
the single-office BP measurement owing to BP variability. In
addition, one-third of the subjects classified as masked hyperten-
sive received antihypertensive treatment and may have taken their
medication a few hours before the visit, leading to decreased BP
levels at the time of measurement. When these drugs have a short
half-life and/or patients have a poor adherence to the prescribed
medication, BP may be higher outside the office, causing a
classification of masked hypertension.
Thus, this indicates that the subjects who are classified as
masked hypertensive are in fact true hypertensives, as is confirmed
by their ambulatory BP value, which is considered to be more
reliable than conventional office BP measurements (2).
Although no statistical difference was given between relative
hazards for sustained and masked hypertension, a potential reason
that subjects classified as masked hypertensive had a lower risk of
cardiovascular morbidity than did those classified as sustained
hypertensive may be explained by the fact that the chance of being
classified as masked hypertensive is higher for mild to moderate
hypertensive patients than it is for severe hypertensive patients
because their BP values are closer to the upper limits.
Therefore, we conclude that masked hypertension is an errone-
ous description of sustained hypertension.
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REPLY
We appreciate the comments by Verberk and colleagues regarding
our recent study (1). We agree with their comments that blood
pressure (BP) level may have been decreased coincidently at the
single-office BP measurement occasion due to BP variability. That
is exactly the nature of “casual” office BP.
As Verberk and colleagues correctly pointed out, one-third of
our study subjects who were classified as masked hypertension
received antihypertensive treatment (1). Baseline proportion of
those with antihypertensive treatment was higher in subjects with
masked hypertension than in those with sustained normal BP (1).
Antihypertensive treatment is an established cause of masked
hypertension, especially when office BP is measured a few hours
after antihypertensive drugs are taken (2). The use of two or more
antihypertensive drugs also increases the odds of masked hyper-
tension compared with the monotherapy in treated hypertensive
patients (3).
As well as subjects with sustained hypertension, those who are
classified as masked hypertension are in fact “true” hypertensives in
terms of their cardiovascular risks. There was no significant
difference between relative hazards for sustained and masked
hypertension (p  0.3 for all primary and secondary outcomes).
The most important factor is that masked hypertension may not be
identified by “casual” office BP measurement, which is usually
“causal” in the worst sense of the word (4). Use of ambulatory BP
monitoring or self-measured home BP can identify masked hyper-
tension. Physicians/health practitioners should recognize at least
the possibility that office BP measurements would miss masked
hypertension. Nevertheless, they do not take into account the
possibility of masked hypertension should the patients develop
organ damage/cardiovascular diseases despite good control of office
BP and other risk factors. If these patients are not identified and do
not receive appropriate treatment, they could develop further organ
damage/cardiovascular diseases.
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